- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

H.R. 3152
U.S. House•In House Committee
Summary
H.R. 3152, the Patent Eligibility Restoration Act of 2025, was introduced in the House on May 1, 2025 by Rep. Kevin Kiley (I) with 1 co-sponsor. It was referred to Judiciary, and last saw action on May 1, 2025: Referred to the House Committee on the Judiciary.
Record
Text
H.R. 3152 has 1 co-sponsor.
hb3152/introduced-in-house.txt119 HR 3152 IH: Patent Eligibility Restoration Act of 2025U.S. House of Representatives2025-05-01text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.I119th CONGRESS 1st SessionH. R. 3152IN THE HOUSE OF REPRESENTATIVESMay 1, 2025Mr. Kiley of California (for himself and Mr. Peters ) introduced the following bill; which was referred to the Committee on the JudiciaryA BILLTo amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes.1.Short titleThis Act may be cited as the Patent Eligibility Restoration Act of 2025 .2.FindingsCongress finds the following:(1)As of the day before the date of enactment of this Act, patent eligibility jurisprudence interpreting section 101 of title 35, United States Code, requires significant modification and clarification.(2)For many years after the original enactment of section 101 of title 35, United States Code, the Supreme Court of the United States and other courts created judicial exceptions to the wording of that section, thereby rendering an increasing number of inventions ineligible for patent protection.(3)Efforts by judges of district courts and courts of appeals of the United States to apply the exceptions described in paragraph (2) to specific circumstances have led to extensive confusion and a lack of consistency—(A)throughout the judicial branch of the Federal Government and Federal agencies; and(B)among patent practitioners.(4)Many judges of the United States Court of Appeals for the Federal Circuit and of various district courts of the United States have explicitly expressed the need for more guidance with respect to the meaning of section 101 of title 35, United States Code, and many patent owners, and persons that engage with patent owners, complain that the interpretation of that section is extremely confusing and difficult to discern and apply with any confidence.(5)Under this Act, and the amendments made by this Act, the state of the law shall be as follows:(A)All judicial exceptions to patent eligibility are eliminated.(B)Any invention or discovery that can be claimed as a useful process, machine, manufacture, or composition of matter, or any useful improvement thereof, is eligible for patent protection, except as explicitly provided in section 101 of title 35, United States Code, as amended by this Act, as described in subparagraphs (D) and (E) of this paragraph.(C)Sections 102, 103, and 112 of title 35, United States Code, will continue to prescribe the requirements for obtaining a patent, but no such requirement will be used in determining patent eligibility.(D)The following inventions shall not be eligible for patent protection:(i)A mathematical formula that is not part of an invention that is in a category described in subparagraph (B).(ii)A mental process performed solely in the mind of a human being.(iii)An unmodified human gene, as that gene exists in the human body.(iv)An unmodified human gene that is isolated from the human body, but otherwise the same as that gene exists in the human body.(v)An unmodified natural material, as that material exists in nature.(vi)A process that is substantially economic, financial, business, social, cultural, or artistic.(E)Under the exception described in subparagraph (D)(vi)—(i)process claims drawn solely to the steps undertaken by human beings in methods of doing business, performing dance moves, offering marriage proposals, and the like shall not be eligible for patent coverage, and adding a non-essential reference to a computer by merely stating, for example, do it on a computer shall not establish such eligibility; and(ii)any process that cannot be practically performed without the use of a machine (including a computer) or manufacture shall be eligible for patent coverage.3.Patent eligibility(a)In generalChapter 10 of title 35, United States Code, is amended—(1)in section 100—(A)in subsection (b), by striking includes a new use of a known process and inserting includes a use, application, or method of manufacture of a known or naturally-occurring process ; and(B)by adding at the end the following:(k)The term useful means, with respect to an invention or discovery, that the invention or discovery has a specific and practical utility from the perspective of a person of ordinary skill in the art to which the invention or discovery pertains.; and(2)by amending section 101 to read as follows:101.Patent eligibility(a)In generalWhoever invents or discovers any useful process, machine, manufacture, or composition of matter, or any useful improvement thereof, may obtain a patent therefor, subject only to the exclusions in subsection (b) and to the further conditions and requirements of this title.(b)Eligibility exclusions(1)In generalSubject to paragraph (2), a person may not obtain a patent for any of the following, if claimed as such:(A)A mathematical formula that is not part of a claimed invention in a category described in subsection (a).(B)A process that is substantially economic, financial, business, social, cultural, or artistic, even though at least 1 step in the process refers to a machine or manufacture.(C)A process that—(i)is a mental process performed solely in the human mind; or(ii)occurs in nature wholly independent of, and prior to, any human activity.(D)An unmodified human gene, as that gene exists in the human body.(E)An unmodified natural material, as that material exists in nature.(2)ConditionsFor the purposes of—(A)subparagraphs (A) and (B) of paragraph (1), the claimed invention shall not be excluded from eligibility for a patent if the invention cannot practically be performed without the use of a machine or manufacture;(B)paragraph (1)(D), a human gene shall not be considered to be unmodified if that human gene is—(i)purified, enriched, or otherwise altered by human activity; or(ii)otherwise employed in a useful invention or discovery; and(C)paragraph (1)(E), a natural material shall not be considered to be unmodified if that natural material is—(i)isolated, purified, enriched, or otherwise altered by human activity; or(ii)otherwise employed in a useful invention or discovery.(c)Eligibility(1)In generalIn determining whether, under this section, a claimed invention is eligible for a patent, eligibility shall be determined—(A)by considering the claimed invention as a whole and without discounting or disregarding any claim element; and(B)without regard to—(i)the manner in which the claimed invention was made;(ii)whether a claim element is known, conventional, routine, or naturally occurring;(iii)the state of the applicable art, as of the date on which the claimed invention is invented; or(iv)any other consideration in section 102, 103, or 112.(2)Infringement action(A)In generalIn an action brought for infringement under this title, the court, at any time, may determine whether an invention or discovery that is a subject of the action is eligible for a patent under this section, including on motion of a party when there are no genuine issues of material fact.(B)Limited discoveryWith respect to a determination described in subparagraph (A), the court may consider limited discovery relevant only to the eligibility described in that subparagraph before ruling on a motion described in that subparagraph..(b)Technical and conforming amendmentThe table of sections for chapter 10 of title 35, United States Code, is amended by striking the item relating to section 101 and inserting the following:101. Patent eligibility..4.Rules of construction(a)Obviousness-Type double patentingNothing in this Act, or any amendment made by this Act, may be construed to affect or alter the judicially-created doctrine of obviousness-type double patenting.(b)Insignificant extra-Solution activityWith respect to the exclusions to patent eligibility described in subparagraphs (A) and (B) of section 101(b)(1) of title 35, United States Code, as added by section 3 of this Act, the inclusion of pre- or post-solution activity by a computer (or other machine or manufacture) in claim language shall not be sufficient to confer patent eligibility on the claim if that computer (or other machine or manufacture) is not necessary to practically perform the invention.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-05-01
- Passed House
- Passed Senate
- Conference
- To President
- Became Law
CRS Summary
The summaries are the Congressional Research Service’s, one per stage. Read them in full.
Introduced in House May 1, 2025
hb3152/introduced-in-house.mdShown Here:
Introduced in House (05/01/2025)
Sponsors
Rep. Kevin Kiley (I) sponsors H.R. 3152, and 1 member has co-sponsored it from the day it was introduced.
Committees
H.R. 3152 went before 1 committee: Judiciary.
Actions
H.R. 3152 has taken 2 actions since May 1, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
May 1, 2025 | House | Introduced in House | ||
May 1, 2025 | House | Referred to the House Committee on the Judiciary.Judiciary Committee |
Votes
H.R. 3152 has not gone to a roll call.
Related bills
1 bill is related to H.R. 3152, as Identical bill.
Titles
H.R. 3152 goes by 3 titles, 1 of them short titles.
- To amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes. — Official Title as Introduced
- Patent Eligibility Restoration Act of 2025 — Display Title
- Patent Eligibility Restoration Act of 2025 — Short Title(s) as Introduced
Lobbying
36 clients hired 34 firms and 230 registered lobbyists who named H.R. 3152 in 137 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Copyright/Patent/Trademark, Trade (domestic/foreign), Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations, Health Issues, Labor Issues/Antitrust/Workplace, Computer Industry.
Clients
Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 36.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| HIGH TECH INVENTORS ALLIANCE | Coalition advocating for policies to promote a balanced and pro-innovation patent system | District of Columbia | 2 | 10 | $450K |
| NOVARTIS | — | District of Columbia | 1 | 7 | — |
| QUALCOMM INCORPORATED | — | District of Columbia | 1 | 5 | $2.8M |
| COALITION FOR 21ST CENTURY PATENT REFORM | — | — | 1 | 5 | $490K |
| INNOVATION ALLIANCE | Informal coalition interested in patent reform | District of Columbia | 1 | 5 | $400K |
| ASSOCIATION FOR MOLECULAR PATHOLOGY | A medical subspecialty professional society | Maryland | 1 | 5 | $352.5K |
| UNITED FOR PATENT REFORM | Coalition comprised of trade groups & companies concerned about weakening U.S. patent laws | District of Columbia | 1 | 5 | $260K |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | Coalition to promote lowering prescription drug prices. | District of Columbia | 1 | 5 | $250K |
| CISCO SYSTEMS INC | IT, networking, and cybersecurity company | District of Columbia | 1 | 5 | $250K |
| AUTM | trsde association for technology transfer/commercialization professionals | District of Columbia | 1 | 5 | $100K |
| US INVENTOR | Inventor Rights Advocacy | Florida | 1 | 5 | $40K |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | LOBBYING | Virginia | 1 | 5 | — |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | — | District of Columbia | 1 | 5 | — |
| GSK (FKA GLAXOSMITHKLINE INC.) | — | District of Columbia | 1 | 5 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | — | District of Columbia | 1 | 5 | — |
| SOFTWARE & INFORMATION INDUSTRY ASSOCIATION | — | District of Columbia | 1 | 5 | — |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | A coalition of organizations working on market-based solutions to drug pricing. | District of Columbia | 1 | 4 | $360K |
| CONSERVATIVES FOR PROPERTY RIGHTS | Coalition | South Carolina | 1 | 4 | $163K |
| 3M COMPANY | Federal Lobbying Activity | District of Columbia | 1 | 4 | — |
| AMAZON.COM SERVICES LLC | — | District of Columbia | 1 | 4 | — |
Firms
Registrants who filed on the bill, by filings.
| Registrant | Clients | Filings | Reported |
|---|---|---|---|
| AKIN GUMP STRAUSS HAUER & FELD | 2 | 10 | $890K |
| FRANKLIN SQUARE GROUP, LLC | 2 | 10 | $600K |
| TWINLOGIC STRATEGIES, LLP | 2 | 10 | $360K |
| NOVARTIS | 1 | 7 | — |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | 1 | 5 | — |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 1 | 5 | — |
| COVINGTON & BURLING LLP | 1 | 5 | $2.8M |
| GSK (FKA GLAXOSMITHKLINE INC.) | 1 | 5 | — |
| IPOLICY SOLUTIONS | 1 | 5 | $352.5K |
| NEOWISE CORP. | 1 | 5 | $40K |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 1 | 5 | — |
| SIIA | 1 | 5 | — |
| WARING FEDERAL STRATEGIES | 1 | 5 | $100K |
| WHITMER & WORRALL, LLC | 1 | 5 | $250K |
| 3M COMPANY | 1 | 4 | — |
| AMAZON.COM SERVICES LLC | 1 | 4 | — |
| AMGEN, INC. | 1 | 4 | — |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 1 | 4 | — |
| CATERPILLAR INC. | 1 | 4 | — |
| ELITE STRATEGIC SERVICES | 1 | 4 | $163K |
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 230.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| GREG BARNES | 1 | 2 | 10 |
| JOSHUA ACKIL | 1 | 2 | 10 |
| KEVIN CUMMINS | 1 | 2 | 10 |
| MATTHEW TANIELIAN | 1 | 2 | 10 |
| ROLAND LITTERST | 1 | 2 | 10 |
| SARAH BETH JANSEN | 1 | 2 | 10 |
| WESLEY MCCLELLAND | 1 | 2 | 10 |
| COURTNEY LEE-ASHLEY | 1 | 1 | 7 |
| COURTNEY PIRON | 1 | 1 | 7 |
| JOSEPH MCGOWAN | 1 | 1 | 7 |
| SARAH DURR | 1 | 1 | 7 |
| TAYLOR BOOTH | 1 | 1 | 7 |
| THOMAS SUTER | 1 | 1 | 7 |
| LEO FARBER | 1 | 1 | 6 |
| ANTON VAN SEVENTER | 1 | 1 | 5 |
| BART FORSYTH | 1 | 1 | 5 |
| BETHANY ABBATE | 1 | 1 | 5 |
| BRIAN POMPER | 1 | 1 | 5 |
| CATHERINE DOUGLAS | 1 | 1 | 5 |
| DANNY BOUNDS | 1 | 1 | 5 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 first_quarter | $12.2M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 third_quarter | $9M | 3rd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 fourth_quarter | $8.4M | 4th Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 second_quarter | $7.6M | 2nd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 second_quarter | $7.4M | 2nd Quarter - Report |
| AMAZON.COM SERVICES LLC | AMAZON.COM SERVICES LLC | 2025 fourth_quarter | $4.6M | 4th Quarter - Report |
| AMAZON.COM SERVICES LLC | AMAZON.COM SERVICES LLC | 2026 first_quarter | $4.4M | 1st Quarter - Report |
| AMAZON.COM SERVICES LLC | AMAZON.COM SERVICES LLC | 2026 second_quarter | $4.4M | 2nd Quarter - Report |
| AMAZON.COM SERVICES LLC | AMAZON.COM SERVICES LLC | 2025 third_quarter | $4.4M | 3rd Quarter - Report |
| NOVARTIS | NOVARTIS | 2026 first_quarter | $3.9M | 1st Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2025 fourth_quarter | $3.6M | 4th Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2025 third_quarter | $3.6M | 3rd Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2026 first_quarter | $2.6M | 1st Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2026 second_quarter | $2.4M | 2nd Quarter - Report |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2026 second_quarter | $2.4M | 2nd Quarter - Report |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | 2026 second_quarter | $1.8M | 2nd Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 third_quarter | $1.7M | 3rd Quarter - Amendme… |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 third_quarter | $1.7M | 3rd Quarter - Report |
| CATERPILLAR INC | CATERPILLAR INC. | 2025 third_quarter | $1.7M | 3rd Quarter - Report |
| CATERPILLAR INC | CATERPILLAR INC. | 2026 first_quarter | $1.7M | 1st Quarter - Report |
Classification
The Congressional Research Service files H.R. 3152 under Commerce, one of its 31 policy areas, and gives it 3 legislative subjects.
CRS Subjects
CRS assigns every bill one policy area from its 31; H.R. 3152’s is Commerce.
hr3152/policy-areas.txtLegislative Subjects
H.R. 3152 carries 3 of CRS’s legislative subjects, from Intellectual property to Judicial review and appeals.
hr3152/subjects.txtSource: congress.gov · legiscan.com
